Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone

INTRODUCTION: Paget’s disease of bone (PDB) is characterised by increased and disorganised bone remodelling affecting one or more skeletal sites. Complications include bone pain, deformity, deafness and pathological fractures. Mutations in sequestosome-1 (SQSTM1) are strongly associated with the dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Cronin, Owen, Forsyth, Laura, Goodman, Kirsteen, Lewis, Steff C, Keerie, Catriona, Walker, Allan, Porteous, Mary, Cetnarskyj, Roseanne, Ranganath, Lakshminarayan R, Selby, Peter L, Hampson, Geeta, Chandra, Rama, Ho, Shu, Tobias, Jon H, Young-Min, Steven, McKenna, Malachi J, Crowley, Rachel K, Fraser, William D, Gennari, Luigi, Nuti, Ranuccio, Brandi, Maria Luisa, Del Pino-Montes, Javier, Devogelaer, Jean-Pierre, Durnez, Anne, Isaia, Giancarlo, Di Stefano, Marco, Guañabens, Núria, Blanch, Josep, Seibel, Markus J, Walsh, John P, Kotowicz, Mark A, Nicholson, Geoffrey C, Duncan, Emma L, Major, Gabor, Horne, Anne, Gilchrist, Nigel L, Boers, Maarten, Murray, Gordon D, Charnock, Keith, Wilkinson, Diana, Russell, R Graham G, Ralston, Stuart H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731944/
https://www.ncbi.nlm.nih.gov/pubmed/31488492
http://dx.doi.org/10.1136/bmjopen-2019-030689

Ejemplares similares

Ejemplares similares